JP2023514567A5 - - Google Patents

Info

Publication number
JP2023514567A5
JP2023514567A5 JP2022548895A JP2022548895A JP2023514567A5 JP 2023514567 A5 JP2023514567 A5 JP 2023514567A5 JP 2022548895 A JP2022548895 A JP 2022548895A JP 2022548895 A JP2022548895 A JP 2022548895A JP 2023514567 A5 JP2023514567 A5 JP 2023514567A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
pharmaceutical composition
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/051215 external-priority patent/WO2021161270A2/en
Publication of JP2023514567A publication Critical patent/JP2023514567A/ja
Publication of JP2023514567A5 publication Critical patent/JP2023514567A5/ja
Pending legal-status Critical Current

Links

JP2022548895A 2020-02-14 2021-02-12 抗il12/il23抗体で潰瘍性大腸炎を治療する安全かつ有効な方法 Pending JP2023514567A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976582P 2020-02-14 2020-02-14
US62/976,582 2020-02-14
PCT/IB2021/051215 WO2021161270A2 (en) 2020-02-14 2021-02-12 Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody

Publications (2)

Publication Number Publication Date
JP2023514567A JP2023514567A (ja) 2023-04-06
JP2023514567A5 true JP2023514567A5 (https=) 2025-08-05

Family

ID=77271772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548895A Pending JP2023514567A (ja) 2020-02-14 2021-02-12 抗il12/il23抗体で潰瘍性大腸炎を治療する安全かつ有効な方法

Country Status (11)

Country Link
US (2) US20210253690A1 (https=)
EP (1) EP4103606A4 (https=)
JP (1) JP2023514567A (https=)
KR (1) KR20220141847A (https=)
CN (1) CN115427444A (https=)
AU (1) AU2021218265A1 (https=)
BR (1) BR112022015996A2 (https=)
CA (1) CA3170677A1 (https=)
IL (1) IL295545A (https=)
MX (1) MX2022009987A (https=)
WO (1) WO2021161270A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3263646A1 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
WO2025029946A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114040A2 (en) * 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
KR20170015920A (ko) * 2014-06-12 2017-02-10 에프. 호프만-라 로슈 아게 FcRn 상호작용이 변화된 항체를 선별하는 방법
CN108290058B (zh) * 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
TWI744617B (zh) * 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法

Similar Documents

Publication Publication Date Title
JP7493569B2 (ja) 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
Tol et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
JP2024016177A5 (https=)
JP2022534020A (ja) Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
JP6097888B2 (ja) 新規使用
JP2020518599A5 (https=)
JP2019523295A5 (https=)
EP4596046A2 (en) Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
IL316408A (en) A safe and effective method for treating psoriasis with a specific anti-IL23 antibody
JP2020500152A5 (https=)
JP2020535149A5 (https=)
IL310216A (en) Methods of treating crohn's disease with anti-il23 specific antibody
JP2021502349A5 (https=)
JP2020502261A5 (https=)
JP2023514567A5 (https=)
JP2024518536A5 (https=)
JP2021532176A5 (https=)
JP2022536088A5 (https=)
JP2021523138A5 (https=)
JP2023544620A5 (https=)
JP2024543885A5 (https=)
JP2022514561A5 (https=)
JP2022534794A5 (https=)
JP2024542777A5 (https=)
JP2021522241A5 (https=)